This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Elonva

Merck & Co., Inc.

Drug Names(s): MK-8962, SCH 900962, Corifollitropin Alfa, Org 36286

Description: Org 36286 is a Sustained Follicle Stimulant (SFS) which is a new category of gonadotropins. Sustained Follicle Stimulants are novel molecules that differ from other classes of gonadotropins. Their specific characteristics result in a sustained action in the human body. Org 36286 may be able to initiate and sustain multifollicular growth for up to an entire week, replacing the need for daily fertility hormone injections during this period.

Deal Structure: Org 36286 was originally developed by Organon, the human pharmaceutical business unit of Akzo Nobel. In November 2007, Schering-Plough announced that it completed the acquisition of Organon BioSciences. Schering-Plough acquired Organon BioSciences from Akzo Nobel for approximately euro 11 billion in cash.

In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and Schering-Plough announced that their merger completed on November 3, 2009.


Elonva News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug